1233142-24-9Relevant academic research and scientific papers
Optimization of a novel kinase inhibitor scaffold for the dual inhibition of JAK2 and FAK kinases
Zificsak, Craig A.,Gingrich, Diane E.,Breslin, Henry J.,Dunn, Derek D.,Milkiewicz, Karen L.,Theroff, Jay P.,Thieu, Tho V.,Underiner, Ted L.,Weinberg, Linda R.,Aimone, Lisa D.,Albom, Mark S.,Mason, Jennifer L.,Saville, Lisa,Husten, Jean,Angeles, Thelma S.,Finn, James P.,Jan, Mahfuza,O'Kane, Teresa M.,Dobrzanski, Pawel,Dorsey, Bruce D.
scheme or table, p. 133 - 137 (2012/02/15)
The elaboration of a novel scaffold for the inhibition of JAK2 and FAK kinases was targeted in order to provide a dual inhibitor that could target divergent pathways for tumor cell progression.
2,7-Pyrrolo[2,1-f][1,2,4]triazines as JAK2 inhibitors: Modification of target structure to minimize reactive metabolite formation
Weinberg, Linda R.,Albom, Mark S.,Angeles, Thelma S.,Breslin, Henry J.,Gingrich, Diane E.,Huang, Zeqi,Lisko, Joseph G.,Mason, Jennifer L.,Milkiewicz, Karen L.,Thieu, Tho V.,Underiner, Ted L.,Wells, Gregory J.,Wells-Knecht, Kevin J.,Dorsey, Bruce D.
scheme or table, p. 7325 - 7330 (2012/02/04)
The JAK2/STAT pathway has important roles in hematopoiesis. With the discovery of the JAK2 V617F mutation and its presence in many patients with myeloproliferative neoplasms, research in the JAK2 inhibitor arena has dramatically increased. We report a nov
